{"entity":{"id":"paper-drilon-entrectinib-ros1-lancet-oncol-2020","kind":"paper","name":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three trials","aka":[],"tldr":"Entrectinib shrank tumours in more than three quarters of patients with ROS1-positive lung cancer and, unlike crizotinib, controlled brain metastases in most patients who had them, earning approval as a first-line option.","summary":"Integrated analysis of 53 ROS1 inhibitor-naive patients with ROS1 fusion-positive non-small-cell lung cancer from the ALKA-372-001, STARTRK-1 and STARTRK-2 trials treated with entrectinib.\n\nObjective response was 77 percent with median duration of response 24.6 months and median progression-free survival 19.0 months; intracranial response was 55 percent in patients with brain metastases.","asOf":"2026-09-17","links":[{"label":"Lancet Oncol 2020","url":"https://doi.org/10.1016/S1470-2045(19)30690-4"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/31838015/"}],"tags":[],"related":[],"cancers":["ros1-positive-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["entrectinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet-oncology"],"dependsOn":[],"notes":[],"journal":"The Lancet Oncology","year":2020,"doi":"10.1016/S1470-2045(19)30690-4","pmid":"31838015","authors":"Drilon A, Siena S, Dziadziuszko R, et al.","paperType":"observational","findings":["Objective response 77 percent; median progression-free survival 19.0 months.","Intracranial response 55 percent."],"whatItMeans":"Entrectinib is a first-line ROS1 inhibitor with brain activity, preferred over crizotinib when brain metastases are present, though repotrectinib and taletrectinib now offer longer control.","caveats":["Single-arm pooled analysis; does not cover the G2032R resistance mutation."],"changedPractice":true,"participants":53},"route":"/key-papers/paper-drilon-entrectinib-ros1-lancet-oncol-2020/","neighbours":{"cancer":[{"id":"ros1-positive-nsclc","kind":"cancer","name":"ROS1-positive non-small-cell lung cancer","route":"/cancers/ros1-positive-nsclc/"}],"drug":[{"id":"entrectinib","kind":"drug","name":"Entrectinib","route":"/drugs/entrectinib/"}],"journal":[{"id":"lancet-oncology","kind":"journal","name":"The Lancet Oncology","route":"/journals/lancet-oncology/"}]}}